# Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD

> **NCT04521452** · PHASE4 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 218 (estimated)

## Conditions studied

- CAVD

## Interventions

- **DRUG:** Evogliptin

## Key facts

- **NCT ID:** NCT04521452
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2024-09
- **Final completion:** 2024-09
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2020-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521452, "Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04521452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*